siao liao-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

ICEsh00ter
06-03

siao liao

Movement Alert｜Abivax S.A. Rises 5.12% in After-Hours Trading, Modest Rebound Following 40% Intraday Plunge on Phase 3 Cancer Safety Concerns

On June 2, Abivax S.A. rose 5.12% in after-hours trading to approximately $76.50 per share, with trading volume of $4.08 million. The move represents a modest technical rebound following a...

Movement Alert｜Abivax S.A. Rises 5.12% in After-Hours Trading, Modest Rebound Following 40% Intraday Plunge on Phase 3 Cancer Safety Concerns

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":571036446871592,"tweetId":"571036446871592","gmtCreate":1780444927220,"gmtModify":1780444930534,"author":{"id":3568262728204718,"idStr":"3568262728204718","authorId":3568262728204718,"authorIdStr":"3568262728204718","name":"ICEsh00ter","avatar":"https://static.tigerbbs.com/e8d9d76c266e1d33abd00a525a8a445c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":94,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>siao liao</p></body></html>","htmlText":"<html><head></head><body><p>siao liao</p></body></html>","text":"siao liao","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/571036446871592","repostId":1142007563,"repostType":2,"repost":{"id":"1142007563","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Market Focus","id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"pubTimestamp":1780435095,"share":"https://ttm.financial/m/news/1142007563?lang=en_US&edition=fundamental","pubTime":"2026-06-03 05:18","market":"hk","language":"en","title":"Movement Alert｜Abivax S.A. Rises 5.12% in After-Hours Trading, Modest Rebound Following 40% Intraday Plunge on Phase 3 Cancer Safety Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1142007563","media":"Market Focus","summary":"On June 2, Abivax S.A. rose 5.12% in after-hours trading to approximately $76.50 per share, with trading volume of $4.08 million. The move represents a modest technical rebound following a...","content":"<p><p>On June 2, Abivax S.A. rose 5.12% in after-hours trading to approximately $76.50 per share, with trading volume of $4.08 million. The move represents a modest technical rebound following a devastating intraday selloff that saw shares plunge over 40%.</p><p>The sharp intraday decline was triggered by the company's disclosure of Phase 3 maintenance trial results for its lead candidate obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint and both the 25 mg and 50 mg dose groups achieved key secondary endpoints, the data was complicated by malignancy cases reported during the trial. Wedbush Securities noted an increasing risk of a black box warning for obefazimod due to the reported malignancies. NASDAQ had halted trading prior to the news release, and upon resumption, shares were immediately met with heavy selling as intraday volume surged to over 14 million shares versus a daily average of approximately 1.1 million. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Rises 5.12% in After-Hours Trading, Modest Rebound Following 40% Intraday Plunge on Phase 3 Cancer Safety Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Rises 5.12% in After-Hours Trading, Modest Rebound Following 40% Intraday Plunge on Phase 3 Cancer Safety Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 05:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 2, Abivax S.A. rose 5.12% in after-hours trading to approximately $76.50 per share, with trading volume of $4.08 million. The move represents a modest technical rebound following a devastating intraday selloff that saw shares plunge over 40%.</p><p>The sharp intraday decline was triggered by the company's disclosure of Phase 3 maintenance trial results for its lead candidate obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint and both the 25 mg and 50 mg dose groups achieved key secondary endpoints, the data was complicated by malignancy cases reported during the trial. Wedbush Securities noted an increasing risk of a black box warning for obefazimod due to the reported malignancies. NASDAQ had halted trading prior to the news release, and upon resumption, shares were immediately met with heavy selling as intraday volume surged to over 14 million shares versus a daily average of approximately 1.1 million. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABVX":"Abivax S.A."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142007563","content_text":"On June 2, Abivax S.A. rose 5.12% in after-hours trading to approximately $76.50 per share, with trading volume of $4.08 million. The move represents a modest technical rebound following a devastating intraday selloff that saw shares plunge over 40%.The sharp intraday decline was triggered by the company's disclosure of Phase 3 maintenance trial results for its lead candidate obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint and both the 25 mg and 50 mg dose groups achieved key secondary endpoints, the data was complicated by malignancy cases reported during the trial. Wedbush Securities noted an increasing risk of a black box warning for obefazimod due to the reported malignancies. NASDAQ had halted trading prior to the news release, and upon resumption, shares were immediately met with heavy selling as intraday volume surged to over 14 million shares versus a daily average of approximately 1.1 million. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","news_type":1,"symbols_score_info":{"ABVX":1}},"isVote":1,"tweetType":1,"viewCount":0,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}